New malaria vaccine effective in clinical trial

Sanaria Inc. an international biotech company in collaboration with the German University of Tübingen, have confirmed that clinical trials of a new malaria vaccine called Sanaria® PfSPZCVac, using fully viable parasites, has achieved 100% protection when evaluated 10 weeks after last dose of vaccine was administered.

A total of 67 healthy adults who had never had malaria were tested during the study. Nine test cases involving persons who received the highest dose of the vaccine thrice at a month’s interval, exhibited the best response. At the close of trials, all nine persons, had 100% protection from the malaria.

A 2015 World Health Organisation report revealed that approximately 438,000 died